Global Predictive and Presymptomatic Testing Market: Industry Analysis and Forecast (2020-2026)
Global Predictive and Presymptomatic Testing Market size was valued at US$ XX Mn in 2019 and the total revenue is expected to grow at 9.6% through 2020 to 2026, reaching nearly US$ XX Mn in the forecast period.
The global Predictive and Presymptomatic Testing Market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Predictive and Presymptomatic Testing Market report also provides trends by market segments, technology, and investment with a competitive landscape.
Global Predictive and Presymptomatic Testing Market Overview:
Presymptomatic testing (PST) is a genetic test carried out on an individual that has no irregular symptoms or an asymptomatic individual to determine whether the person has a hereditary disease-causing mutation or any genetic disorders that can lead to genetic disorders in the future. Further, this test is carried out to identify whether a person will develop a genetic disorder in the future or not and reduce the rising occurrence of genetic disorders. Predictive genetic testing is the use of a genetic test in an asymptomatic person to predict future risk of disease. These tests represent a new and growing class of medical tests, differing in fundamental ways from conventional medical diagnostic tests.
Global Predictive and Presymptomatic Testing Market Dynamics:
The predictive and presymptomatic testing market expected to grow at CAGR of 9.6% during the forecast year of 2020-2026 due to growing genetic disorders and genetic counseling. Resources and technological advancement have played a great role in genetic counseling. As per medical conditions, 10% of individuals are suffering from genetic defects, however, it's a minor disease. Some of the common genetic disorders are Down syndrome, Thalassemia, Cystic fibrosis, sickle cell anemia, and various others.
As per Proceeding National Academy of Science of North America, around 2.7 billion people (36% of the total world population) worldwide are the carrier of at least one mutation that causes AR-IRD that is autosomal recessive (AR) inherited retinal diseases (IRDs). Moreover, modern technologies and the latest innovations concerning genetic disorders are boosting the market growth of the predictive and presymptomatic testing market. Also, there is no cure for genetic disorders; they can only be treated and not cured fully.
Global Predictive and Presymptomatic Testing Market Segment Analysis:
By Condition, the segment is divided into Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer’s disease, Multiple Endocrine Neoplasia Type – 2, Haemochromatosis. Breast and Ovarian Cancer is dominating the conditioning segment of the Predictive and Presymptomatic Testing market and is estimated to witness the highest CAGR in the forecast period of 2020-2026. Cancers included in the conditioning segment are not genetic disorders but are greatly controlled by genes in the body and are passed from one generation to another. The identification of BRCA1 and BRCA that Breast Cancer Gene in 1994-1995 leads to the testing of presymptomatic DNA testing for autosomal dominant hereditary breast and ovarian cancer.
Every healthy mutation carrier of the BRCA gene has a high risk of breast cancer and ovarian cancer for a lifetime. Moreover, India and America are the countries where women are highly suffered from breast cancer every year. In India, the total number of breast cancer frequency cases was valued at 7,12,758 in 2020 and estimated to reach 8,06,218 by 2025 in women. The number of breast cancer cases that is 2,38,908 is expected to be the most common cancer forecast period, followed by cancer in the lung (1,11,328) and mouth (90,060) in the future.
Additionally, around 2.3 million breast cancer cases were reported in women and 685000 deaths were caused due to breast cancer globally in the year 2020. Further, the rate has decreased due to high technological investments and precise medications with advanced therapy like oral chemotherapy and a target drug delivery system.
To know about the Research Methodology :- Request Free Sample Report
Global Predictive and Presymptomatic Testing Market Regional Insights:
North America is dominating the predictive and presymptomatic testing market regional insight. The major countries of North America are the US, Mexico, and Canada. Among these, the US was valued at USD 1.12 billion in the year 2020. In 2020, an estimated 276,480 new cases of proliferating breast cancer were diagnosed in women in the U.S. 65% of breast cancer cases are diagnosed at a localized stage, in which 5-year survival is 98%. Additionally, North America is ranked highest in breast cancer treatment due to the occurrence of breast cancer cases in women. Further, the high technological investment in the region with growing healthcare facilities with advanced infrastructure are fuelling the market growth of predictive and presymptomatic testing in the regional market.
Global Predictive and Presymptomatic Testing Market 1
The objective of the report is to present a comprehensive analysis of the global Predictive and Presymptomatic Testing Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the global Predictive and Presymptomatic Testing Market dynamics, structure by analyzing the market segments and project the global Predictive and Presymptomatic Testing Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the global Predictive and Presymptomatic Testing Market make the report investor’s guide.
For more information of visit:https://www.maximizemarketresearch.com/market-report/global-predictive-and-presymptomatic-testing-market/112656/
Global Predictive and Presymptomatic Testing Market Scope: Inquire before buying
Global Predictive and Presymptomatic Testing Market 2
Global Predictive and Presymptomatic Testing Market, by Region
• North America
• Europe
• Asia Pacific
• The Middle East and Africa
• South America
Global Predictive and Presymptomatic Testing Market Key Player
• 23andMe, Inc.
• Abbott Molecular, Inc.
• BioAxis DNA Research Centre Private Limited
• Color Genomics, Inc.
• Direct Laboratory Services LLC (DirectLabs)
• Gene by Gene Ltd.
• Genomic Diagnostics
• Mapmygenome
• Myriad Genetics, Inc.
• Pathway Genomics Corporation
• Positive Bioscience, Inc.
• Quest Diagnostics, Inc
Maximize Market Research offers customization of reports according to the specific requirement of our clients.
This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
